Aldeyra falls after FDA extends review of eye disease drug

Aldeyra Therapeutics

16/12/2025 10:36

** Shares of Aldeyra Therapeutics ALDX.O fall 15.5% to $3.37 premarket

** Co says U.S. FDA has extended the review of its drug reproxalap for treating symptoms of dry eye disease

** Says FDA will now give its decision on March 16, 2026, instead of its previous action date of December 16

** The FDA has made no other requests and did not identify any other specific issues with the marketing application - ALDX

** As of last close, stock down 20% YTD

 (Reporting by Christy Santhosh)

 ((Christy.Santhosh@thomsonreuters.com))